pharmafileSeptember 13, 2018
Tag: Takeda , acquisition , Deerfield
The Deerfield site employs around one fifth of Takeda's 5000 US employees. Thus although a proportion of those workers affected will be provided with job offers and the chance of relocation, the move is set to cause significant disruption. The company did not provide details as to what percentage of workers will lose their jobs.
The move has come after Takeda was acquired by the Dublin headquartered and London Listed pharma company Shire for £45.3 billion. Meanwhile the acquisition has caused discontent within the Takeda family with company heir Kazu Takeda.
Kazu Takeda said to British newspaper The Times: "We understand that scaling up is necessary, but Takeda management has to think about the traditional corporate culture and the health of the company. Hasty decisions on big deals should be avoided. It will lead to disaster if there are large-scale mergers and acquisitions without careful consideration"
Meanwhile commenting on the move from Deerfield a spokersperson for Takeda's US operations said:"This move, while difficult, will allow closer collaboration across Takeda to best position our future pipeline for success. It will also simplify our existing Takeda U.S. operations."
Louis Goss
-----------------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: